Posted on August 10, 2018

RCSI and Bayer have today announced a research collaboration that aims to improve treatments for people with severe haemophilia. The project will explore new treatments that can be tailored to the severity of each individual’s condition in order to safely and effectively promote blood clotting in people with haemophilia.

Haemophilia is an inherited bleeding disorder caused by the lack of a key blood clotting protein, known as factor VIII (FVIII). This results in prolonged bleeding that is difficult to stop unless the condition is recognised and treated. Haemophilia predominantly affects men, with approximately 1 in 4000 males in Ireland affected.

The research study is led by Dr Roger Preston, Lecturer in Vascular Biology at the Irish Centre for Vascular Biology and Department of Molecular and Cellular Therapeutics, RCSI and is funded by a Special Project Award of €200,000 from Bayer. The award was made under the Bayer Haemophilia Awards Program, a prestigious international award programme that supports basic and clinical research in haemophilia. The programme seeks to support the development of the next generation of care and treatment options for people with haemophilia worldwide.

Individuals with severe haemophilia A are at an increased risk of bleeding as they possess factor VIII levels of <1% of that observed in individuals without haemophilia. This is normally treated by regular administration of ‘replacement’ factor VIII.

Dr Roger Preston said: “The aim of our study is to engineer new therapeutics with clotting properties that can be ‘tuned’ to match the needs of each person being treated. We hope to develop treatments that can promote blood clotting with increased precision in order to improve the quality of life for people with haemophilia and other individuals at increased risk of bleeding”.

Dr Roger Preston, RCSIDr Roger Preston, Lecturer in Vascular Biology at the Irish Centre for Vascular Biology and Department of Molecular and Cellular Therapeutics, RCSI

RCSI CEO, Professor Cathal Kelly said: “RCSI is delighted to announce this collaboration between Dr Preston and Bayer. This partnership exemplifies how collaboration between academia and industry can help improve the health of people with haemophilia through the high quality, impactful scientific research taking place at the Irish Centre for Vascular Biology here at RCSI.”

“Since its establishment 15 years ago, the ultimate goal of Bayer Haemophilia Awards Program (BHAP) has been to support research that has the potential to have a significant impact on our understanding of haemophilia and bleeding disorders,” said Dr Tristan Cooper, Bayer Ltd. Medical Director. “BHAP continues to be a tangible reflection of Bayer’s ongoing commitment to research and advancing scientific knowledge that improves patient care. We are proud to recognise and award Dr Preston for his expertise and commitment in his field.”

Dr Preston was previously awarded an Early Career Investigator Award from Bayer in 2014 and this new project will build on his initial research in this field.

About RCSI
RCSI is ranked among the top 250 (top 2%) of universities worldwide in the Times Higher Education World University Rankings (2018) and its research is ranked first in Ireland for citations. It is an international not-for-profit health sciences institution, with its headquarters in Dublin, focused on education and research to drive improvements in human health worldwide. RCSI is a signatory of the Athena SWAN Charter.

About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to

Applications are open for 2024 now.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.